Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities.
about
XAP2 inhibits glucocorticoid receptor activity in mammalian cellsNaturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanismFinding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic targetThe role of mTOR signaling in Alzheimer diseaseRapalogs and mTOR inhibitors as anti-aging therapeuticsRapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathyDrug discovery and natural products: end of an era or an endless frontier?In Silico Insight into Potent of Anthocyanin Regulation of FKBP52 to Prevent Alzheimer's Disease.Applications of high content screening in life science researchA novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression.Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling.Short-term recognition memory impairment is associated with decreased expression of FK506 binding protein 51 in the aged mouse brain.Nitroso Diels-Alder (NDA) reaction as an efficient tool for the functionalization of diene-containing natural productsMonitoring molecular-specific pharmacodynamics of rapamycin in vivo with inducible Gal4->Fluc transgenic reporter mice.Biosynthesis of the immunosuppressants FK506, FK520, and rapamycin involves a previously undescribed family of enzymes acting on chorismateOrganization and function of the FKBP52 and FKBP51 genes.Modeling and rescue of the vascular phenotype of Williams-Beuren syndrome in patient induced pluripotent stem cells.Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A.Syntheses and biological activity studies of novel sterol analogs from nitroso Diels-Alder reactions of ergosterol.Role of immunophilins in recovery of erectile function after cavernous nerve injury.Neurotrophic natural products: chemistry and biology.Natural product scaffolds as leads to drugs.Bending tau into shape: the emerging role of peptidyl-prolyl isomerases in tauopathiesThe generation of "unnatural" products: synthetic biology meets synthetic chemistry.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Microbial natural products: molecular blueprints for antitumor drugs.Industrial natural product chemistry for drug discovery and development.Label-free, high content screening using Raman microspectroscopy: the toxicological response of different cell lines to amine-modified polystyrene nanoparticles (PS-NH2).An overview of rapamycin: from discovery to future perspectives.Where are the new medicines? The case for terrestrial microorganisms.Applications of Nonenzymatic Catalysts to the Alteration of Natural Products.Promiscuity of a modular polyketide synthase towards natural and non-natural extender units.The RET51/FKBP52 complex and its involvement in Parkinson disease.Rem, a member of the RGK GTPases, inhibits recombinant CaV1.2 channels using multiple mechanisms that require distinct conformations of the GTPase.Draft Genome Sequence of Streptomyces rapamycinicus Strain NRRL 5491, the Producer of the Immunosuppressant Rapamycin.Toxicological assessment of nanomaterials: the role of in vitro Raman microspectroscopic analysis.Endogenous TRPV4 Expression of a Hybrid Neuronal Cell Line N18D3 and Its Utilization to Find a Novel Synthetic Ligand.Evaluation of WO2011045166A1, Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction.Site-specific bioalkylation of rapamycin by the RapM 16-O-methyltransferase.
P2860
Q24317168-C3F9826C-A37C-44E2-8F90-BBBE169E4321Q24595310-AAB5B7C4-E3AB-4C95-9EF0-D0C2455A5385Q27024547-2CC228BD-1FCA-48FE-B5CE-3A2FEB5C3FA5Q28256247-6D10A1C3-9389-4C85-BEA2-C0D8D790DAA7Q28286510-6628F1C0-20E3-4C95-A6B0-7CF9EDE50414Q30662442-061F8AC5-3231-405B-A5BC-FDCDD4B46137Q30866998-516CBFBA-22DF-4FF3-9FF4-BD3925DE6DE8Q33678309-856E8A63-1D11-49BA-9EFD-32EDA445733BQ33738142-0F18152A-BBA9-41CE-BAF0-BC40AD938A9DQ33784612-CC3CFDD9-C82C-406E-BE03-E2081BEEAE9EQ33986353-E253AF11-0B06-4C84-A99D-4A8C81AFDC2DQ34080397-EFE578A9-C518-4FC8-AA25-B9A06FD84FDDQ34167537-34A5BA2F-81D9-46D3-9B1B-04101CB2E466Q34192264-78CF8D95-E81D-404E-B221-BE2B7D482CE4Q34720963-F0B18133-91CB-4CCB-B2A6-DDC3B7D1A124Q35165005-15E4EC83-4AAE-4BF1-979E-D87E9FC1ABAEQ36861726-5296A122-766C-4954-8DAD-063A93FA71C1Q36917696-129D76BA-A183-4127-AA80-A046C5D92FCAQ37381024-0B552B92-C15B-48D7-B782-B0D833C7D19FQ37408365-31E5B5F3-C50A-43C8-A3A1-C7FADE41EDB9Q37623342-56A32A60-66B4-4E27-8CA7-BB2F113E1169Q37855860-E5888F47-BCA9-4FAD-A59E-5C83FF66DB03Q37869409-0E27FB47-B78D-4C8B-83B5-E30B436F9A29Q38022529-9617F5AF-AC84-4C91-B25D-49CE2F4286FEQ38065993-CCE85C3F-577C-4E04-95DF-20DE73F81B7CQ38133765-5DABB4F2-980B-48E0-B884-1589FF9C4087Q38154186-7238801C-050B-4F95-BC26-DDAA056AFFBEQ38694347-F2491F03-DF4C-4B85-9460-E8D86745573BQ38822715-16A74B46-C913-4828-B83B-E0D8C8F986E6Q39151902-0904ECD2-5763-43C0-B6AE-651F078CEE5BQ39350547-08337E7A-60D1-4B68-BC21-B3188E5A967CQ39417729-EFDE247D-ECBD-4422-9DCF-DBFA5F0DD81FQ39707711-4A45CE5A-7D61-46E1-9CF5-39C2834831EDQ39724660-7A1B8C48-6E16-4FD8-89FA-5FD76791D887Q41909678-8D9BDAA7-0C1F-4922-89F7-876C8BF65F0FQ47267641-E7C70D5B-B7C1-4A0C-A657-F1CDDE7A6797Q48091207-A14BEE8A-3C12-486E-BF89-81C4D5CD5279Q48191211-011A6921-F865-4CB8-B493-0586745FF4C0Q49272873-329AAD53-6E85-4072-B9D9-8AA256C6A0CB
P2860
Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@ast
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@en
type
label
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@ast
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@en
prefLabel
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@ast
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@en
P2093
P2860
P356
P1476
Binding of rapamycin analogs t ...... ir neuroprotective activities.
@en
P2093
Andrew Wood
Benfang Ruan
David von Schack
Edmund I Graziani
Frank E Koehn
Frann Bennett
Guy T Carter
Jerauld Skotnicki
P2860
P356
10.1073/PNAS.0710424105
P407
P577
2007-12-27T00:00:00Z